Divisions over lecanemab: keeping an open mind
Lancet
.
2024 Sep 21;404(10458):1077.
doi: 10.1016/S0140-6736(24)02075-0.
Author
The Lancet
PMID:
39306453
DOI:
10.1016/S0140-6736(24)02075-0
No abstract available
Publication types
Editorial
MeSH terms
Antibodies, Monoclonal, Humanized* / pharmacology
Humans
Substances
lecanemab
Antibodies, Monoclonal, Humanized